null

null

null

null

0.49x Total Debt / Equity (Conservative)

Low-moderate; Lexicon carries ~$200M long-term debt, mostly fixed-rate; 200bps rise adds ~$4M annual interest expense, manageable given cash reserves

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Active pharmaceutical ingredient sourcing from China/India CMOs; single-source API manufacturing for sotagliflozin creates concentration risk

Minimal international revenue currently; EUR exposure via European partnerships negligible; sovereign currency devaluation risk is near-zero material impact

Primarily US-based revenues; limited EUR and GBP exposure from EU/UK partnership royalties; currency devaluation impact on total revenue estimated below 5%

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Yes; single CMO dependency for sotagliflozin API manufacturing likely exceeds 30% of COGS input; non-substitutable short-term without 12-24 month transition

Cloud disruption risk is low; core operations are lab-based R&D and commercial pharma sales, not cloud-native SaaS; 30-day termination causes IT disruption only

Secondary cloud dependency for ERP, CRM, and clinical data systems; migration disruptive but feasible within 60-90 days with pre-negotiated backup vendors

Moderate API coupling via Elanco and Sanofi partnership data systems; proprietary clinical data formats create moderate switching friction but no catastrophic lock-in

Low Howey risk; revenue derived from FDA-approved drug sales and licensing royalties, constituting standard commercial pharmaceutical transactions, not securities

Very High

Moderate GDPR exposure via EU clinical trial patient data; CCPA exposure limited; estimated compliance cost $2-5M annually; no material enforcement history noted

Low; Lexicon holds niche rare-disease and heart-failure market positions; XERMELO and sotagliflozin lack dominant market share triggering meaningful antitrust scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional drug sales (~70%) plus licensing/royalty recurring streams (~30%); no subscription model; revenue mix shifting toward royalties post-commercialization deals

Drug product sales (XERMELO, sotagliflozin INPEFA) plus milestone payments and royalties from Sanofi/Elanco licensing agreements

Branded pharmaceutical pricing with WAC/net price spread; INPEFA WAC ~$550/month; rebate pressure from PBMs compresses net price by estimated 30-45%

Moderate; novel mechanism in heart failure supports premium pricing but competitive SGLT2 class (Jardiance, Farxiga) caps upside; pricing power rated 5/10

65-75% gross margin target; currently constrained by CMO manufacturing costs and royalty obligations; scale improvement expected as INPEFA volume grows

No free-rider problem; prescription drug model requires physician prescribing and payer coverage; patient assistance programs create cost but not free-rider leakage

Sublinear growth possible; commercial sales force scales near-linearly but R&D and G&A are largely fixed; doubling revenue does not require doubling headcount

Marginal cost of revenue growth is primarily sales force expansion and manufacturing volume; estimated 40-50% incremental margin at scale for INPEFA

Not applicable; Lexicon operates no franchise network

At 10x scale, physician detailing cost per new prescriber declines; estimated CAC payback period 18-24 months; payer contracting costs increase nonlinearly at scale

No meaningful network effects; pharmaceutical adoption driven by clinical evidence, physician relationships, and payer coverage, not user-network dynamics

-47.4% Return on Assets (Negative equity)

Tier 2 moderate resilience; heart failure and carcinoid syndrome are chronic conditions requiring ongoing treatment; however, payer coverage and patient cost-sharing create recession vulnerability

Physicians (cardiologists, endocrinologists, oncologists) and institutional health systems prescribing INPEFA and XERMELO; no single customer >10% of revenue

Pharmacy benefit managers and payers controlling formulary access; Medicare/Medicaid represent significant payer concentration risk given Part D negotiation dynamics

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.0% CapEx / Revenue (Low-CapEx Asset-Light)

0001062822

LXRX